Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
PHASE3WithdrawnINTERVENTIONAL
0
Timeline
Start Date
January 31, 2015
Primary Completion Date
April 30, 2015
Study Completion Date
April 30, 2015
Conditions
Infections, Papillomavirus
Interventions
PROCEDURE
Blood sampling
Blood samples will be collected from all subjects at Year 6.5
NCT02100618 - Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study | Biotech Hunter | Biotech Hunter